Kai-Michael Beeh, ERS 2020 – Green Inhalers
Following his presentation at the ERS Congress, Dr. Kai-Michael Beeh (Insaf Respiratory Research Institute, Wiesbaden, Germany) caught up with us to continue the discussion around green inhalers.
1. Could you give us an overview of the environmental impact of asthma inhaler use? (0:22)
2. How do dry powder inhalers compare to metered-dose inhalers in terms of their carbon footprint? (0:54)
3. What factors should be considered when prescribing dry powder inhalers and how can we facilitate this process for patients? (1:23)
4. What would be the environmental impact if every asthma patient switched to a green inhaler? (1:59)
5. How can we further reduce the carbon footprint of asthma therapy? (2:36)
Speaker disclosure: The institutions Kai-Michael Beeh represents have received compensation for services on advisory boards or consulting from AstraZeneca, Berlin Chemie, Boehringer, Chiesi, GSK, Novartis, Pohl Boskamp, Teva and Sanofi. They have also received compensations for speaker activities in scientific meetings supported by AstraZeneca, Berlin Chemie, Boehringer, Chiesi, GSK, Novartis, Pohl Boskamp, Teva, Sanofi and compensation for design and performance of clinical trials from AstraZeneca, Boehringer, GSK, Novartis, Pearl Therapeutics, Teva and Stern.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress Congress 2020.
Share this Video
Related Videos In Asthma
Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]
Isaac Schmale, AAAAI 2023: Signs and symptoms of aspirin-exacerbated respiratory disease and its treatment paradigm
touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]
Ronald Strauss, AAAAI 2023: Hot topics to explore in the field of respiratory medicine
touchRESPIRATORY were delighted to speak with a valued member of our Editorial Board for touchREVIEWS in Respiratory & Pulmonary Diseases, Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), about the areas in the field of respiratory medicine that he is most looking forward to exploring in 2023. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!